• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: GENZYME BIOSURGERY SYNVISC (SYNVISC); INTRA-ARTICULAR HYALURONIC ACID

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

GENZYME BIOSURGERY SYNVISC (SYNVISC); INTRA-ARTICULAR HYALURONIC ACID Back to Search Results
Device Problem Patient-Device Incompatibility (2682)
Patient Problem Joint Swelling (2356)
Event Date 11/01/2014
Event Type  Injury  
Event Description
This unsolicited device case from (b)(6) was received on (b)(6) 2014 from a physician.This case is cross reference to case id: (b)(4) and (b)(4) (same reporter, cluster).This case concerns a (b)(6) male pt who had effusion nos after receiving treatment with synvisc.The pt's medical history was significant for use of synvisc (2 sessions).No relevant past drugs, concomitant medications and concurrent conditions were reported.On an unk date in (b)(6) 2014, the pt received treatment with synvisc injection at a dose of 2 ml, once (third session) (route of administration, indication, lot/batch number and exp date; not reported) into an unspecified joint.On an unk date in (b)(6) 2014, about one week later, the pt was presented with an effusion.It was reported that the pt's physician did not manage to perform a puncture and prescribed an unspecified anti-inflammatory drug.On a unk date, a sometime later, the pt went to see his rheumatologist who performed a puncture (unk amount aspirated) and results a puncture (unk amount aspirated) and results showed that the liquid was free of germs.The rheumatologist prescribed an oral unspecified corticoid drug to the pt.On an unk date, the pt recovered from the event.Action taken: stopped temporarily.Outcome: recovered/resolved.A pharmaceutical technical complaint (ptc) was initiated and results were pending for the same.Seriousness criteria: required intervention (administered oral unspecified corticoid drug).French imputability number: (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SYNVISC (SYNVISC)
Type of Device
INTRA-ARTICULAR HYALURONIC ACID
Manufacturer (Section D)
GENZYME BIOSURGERY
ridgefield NJ
Manufacturer Contact
kristen sharma, md
55 corp dr
mail stop: 55c-235a
bridgewater, NJ 08807
9089812784
MDR Report Key4369867
MDR Text Key16303188
Report Number2246315-2014-75391
Device Sequence Number1
Product Code MOZ
Combination Product (y/n)N
PMA/PMN Number
P940015
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional
Type of Report Initial
Report Date 12/17/2014
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Other
Initial Date Manufacturer Received 12/17/2014
Initial Date FDA Received12/23/2014
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Treatment
CON MEDS = UNK; SYNVISC (PREV)
Patient Outcome(s) Required Intervention;
Patient Age60 YR
-
-